Sanna Bastiano
Known title: EVP, Cell & Genetic TherapiesCIK: 0001829069
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.
Transaction History
| ACET | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,850 | $998K | 5/8/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 422 | $148K | 5/5/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 728 | $256K | 5/3/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,053 | $719K | 5/3/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,411 | $494K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 169 | $60K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 42 | $15K | 5/2/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 874 | $285K | 4/12/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,625 | $860K | 4/12/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 4,068 | $1.3M | 4/12/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 211 | $66K | 4/4/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 94 | $30K | 4/4/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 90 | $29K | 4/4/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 96 | $30K | 4/4/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 31 | $10K | 4/4/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 1,466 | $460K | 3/31/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,482 | $746K | 3/16/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 264 | $79K | 3/16/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 3,970 | $1.1M | 2/24/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 3,750 | $1.1M | 2/17/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,902 | $571K | 2/14/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 279 | $84K | 2/14/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 4,340 | $1.3M | 2/13/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 113 | $34K | 2/13/2023 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 902 | $265K | 2/10/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 7,866 | $0 | 2/1/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 9,092 | $0 | 2/1/2023 | View on chart |
| VRTX | ▲ Buy | Grant | 12,314 | $0 | 2/1/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 106 | $34K | 1/31/2023 | View on chart |
| VRTX | ▼ Sell | Open Market | 56 | $17K | 11/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 39 | $12K | 11/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 100 | $31K | 11/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 81 | $25K | 11/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 12 | $4K | 11/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 10 | $3K | 11/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 22 | $7K | 11/2/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 768 | $240K | 11/1/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 1,503 | $451K | 10/18/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 288 | $87K | 10/18/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 766 | $212K | 8/1/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 7 | $2K | 5/16/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 15 | $4K | 5/16/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 8 | $2K | 5/16/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 7 | $2K | 5/16/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 8 | $2K | 5/16/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 36 | $10K | 5/4/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 20 | $5K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 90 | $23K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 43 | $11K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 75 | $19K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 23 | $6K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 4 | $1K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 65 | $17K | 5/2/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 766 | $212K | 4/29/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 327 | $90K | 4/7/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 30 | $8K | 4/7/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 204 | $56K | 4/7/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 3,163 | $871K | 4/5/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 257 | $69K | 4/4/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 305 | $81K | 4/4/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 1,344 | $354K | 4/1/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 2,122 | $531K | 3/17/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 3,439 | $800K | 2/17/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 979 | $233K | 2/10/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 670 | $168K | 2/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 141 | $35K | 2/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 16 | $4K | 2/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 149 | $38K | 2/2/2022 | View on chart |
| VRTX | ▼ Sell | Open Market | 64 | $16K | 2/2/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 526 | $128K | 2/1/2022 | View on chart |
| VRTX | ▲ Buy | Grant | 11,628 | $0 | 2/1/2022 | View on chart |
| VRTX | ▲ Buy | Grant | 12,314 | $0 | 2/1/2022 | View on chart |
| VRTX | ▼ Sell | Tax Withholding | 766 | $142K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target
Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.